These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 22895144)

  • 1. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
    Fennell DA; McDowell C; Busacca S; Webb G; Moulton B; Cakana A; O'Byrne KJ; Meerbeeck JV; Donnellan P; McCaffrey J; Baas P
    J Thorac Oncol; 2012 Sep; 7(9):1466-70. PubMed ID: 22895144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
    O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
    Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
    Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
    J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
    Busacca S; Chacko AD; Klabatsa A; Arthur K; Sheaff M; Barbone D; Mutti L; Gunasekharan VK; Gorski JJ; El-Tanani M; Broaddus VC; Gaudino G; Fennell DA
    PLoS One; 2013; 8(6):e65489. PubMed ID: 23762382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Govindan R; Kratzke RA; Herndon JE; Niehans GA; Vollmer R; Watson D; Green MR; Kindler HL;
    Clin Cancer Res; 2005 Mar; 11(6):2300-4. PubMed ID: 15788680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
    J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
    Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
    Gregorc V; Zucali PA; Santoro A; Ceresoli GL; Citterio G; De Pas TM; Zilembo N; De Vincenzo F; Simonelli M; Rossoni G; Spreafico A; Grazia Viganò M; Fontana F; De Braud FG; Bajetta E; Caligaris-Cappio F; Bruzzi P; Lambiase A; Bordignon C
    J Clin Oncol; 2010 May; 28(15):2604-11. PubMed ID: 20406925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
    Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
    Fennell DA; C Steele JP; Shamash J; Sheaff MT; Evans MT; Goonewardene TI; Nystrom ML; Gower NH; Rudd RM
    Lung Cancer; 2005 Feb; 47(2):277-81. PubMed ID: 15639727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.
    Ellithy MM; El Baghdady NS; El Wakeel LM; Abdeltawab KA; Badary OA
    Am J Clin Oncol; 2013 Oct; 36(5):514-8. PubMed ID: 22781392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
    Krug LM; Heelan RT; Kris MG; Venkatraman E; Sirotnak FM
    J Thorac Oncol; 2007 Apr; 2(4):317-20. PubMed ID: 17409804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
    Otterson GA; Herndon JE; Watson D; Green MR; Kindler HL;
    Lung Cancer; 2004 May; 44(2):251-9. PubMed ID: 15084390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.